48Hour Discovery receives Government of Canada funding to develop technology that maximizes success of drug discovery

Thu, Apr 18, 2019

New technology platform would deliver orally available small molecule therapeutics for a wide range of targets EDMONTON, ALBERTA (April 18, 2019) – 48Hour Discovery (48HD) today announced that it will  receive up to $193,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to research and develop a technology that expedi...Read More


Precision Therapeutics' subsidiary TumorGenesis and its partner 48Hour Discovery Inc. receive Alberta Innovates Product Demonstration Program grant to support development of novel cancer treatments

Tue, Apr 16, 2019

Collaboration receives $300,000 CAD grant to further develop and commercialize TumorGenesis oncology discovery technologies MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) – Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through ...Read More


48Hour Discovery announces the appointment of David Alton as Director of Business Development

Mon, Mar 11, 2019

EDMONTON, ALBERTA (March 11, 2019) – 48Hour Discovery Inc. announced the appointment of David Alton as the Director of Business Development, effective March 11, 2019. Alton will bring extensive experience in leadership to the management team, strengthen the Company’s business infrastructure and develop new investment opportunities. “We are excited to have David join our t...Read More


48Hour Discovery proud to sponsor the Canadian Glycomics Symposium 2018

Tue, Apr 17, 2018

EDMONTON (April 17 2018)–48Hour Discovery Inc. (48HD) is pleased to announce a sponsorship with the Canadian Glycomics Network (GlycoNet) to support the Canadian Glycomics Symposium 2018. The Symposium affords an exciting opportunity to glimpse the frontiers of knowledge in the emerging field of glycomics. This annual Symposium welcomes more than 200 researchers, trainees, and stakehold...Read More


Join Us for an Inside Look of our Technology

Wed, Apr 11, 2018

Join us for an exclusive tour of our molecular discovery platform. This half day workshop will take you through our exciting new technology and will involve hands-on experiments and real-time data analysis. The workshop will describe how you can leverage our molecular discovery pipeline for your own research endeavours. Purchase tic...Read More


48Hour Discovery Enters into Agreement with TumorGenesis

Thu, Mar 29, 2018

Edmonton-based start-up to develop personalized cancer therapy models: EDMONTON (March 29, 2018)–48Hour Discovery Inc. (48HD) announced today that they have signed an agreement with Precision Therapeutics Inc. (NASDAQ:AIPT) and its wholly owned subsidiary, TumorGenesis Inc. 48HD will grant access to its patented molecular discovery technology, enabling TumorGenesis Inc. to develop precision cancer therapy models. 4...Read More


GlycoNet Agreement with 48Hour Discovery

Thu, Oct 19, 2017

“We are extremely pleased to see a core service being commercialized… Supporting 48Hour Discovery fits with our strategic goals of spurring job creation and fostering start-up success in Canada.” said Dr. Todd Lowary, GlycoNet Scientific Director. To see full article, ...Read More


Highlight of 48Hour Discovery in the Edmonton Journal

Wed, Aug 16, 2017

Our company was recently highlighted in the Edmonton Journal: Edmonton startup wants to put Alberta at epicentre of molecular discoveries A University of Alberta biotechnology spinoff wants to put Edmonton at the epicentre of molecular discoveries by creating an immense searchable database that could speed up and drive down the cost of research and developme...Read More